ClinMet and Collaborators to Present Data Regarding Metabolomics and Diabetic Complications at Kidney Week 2014
SAN DIEGO, CA (PRWEB) November 13, 2014 -- ClinMet today announced that company scientists and collaborators, led by ClinMet scientific founder, Kumar Sharma, M.D., F.A.H.A., Professor of Medicine and the Director of Center for Renal Translational Medicine and the Institute of Metabolomic Medicine at the University of California, San Diego will present new findings on the relationship between mitochondria function and diabetic complications, and the use of metabolomics to understand such at Kidney Week 2014. The annual scientific meeting of the American Society of Nephrology is being held November 11 - 14 in Philadelphia, Pennsylvania.
Oral Presentations:
Friday November 14 - “Mitochondria and Metabolomics in Diabetic Complications”
Speaker: Kumar Sharma, M.D., F.A.H.A
Session: Breaking Bad: The New Chemistry and Metabolomics of Cardiovascular Disease”
Location: Ballroom A
Time: 3:36 - 4:00 pm
Saturday November 15 - “Restoring Mitochondrial Superoxide Levels with Bendavia™ Protects against Progression of Diabetic Kidney Disease in db/db Mice”
Speaker: Satoshi Miyamoto, M.D., Ph.D.
Annual Meeting: Abstract Sessions
Time: 4:30 pm
Poster Presentations:
Thursday November 13 - “High Spatial and Spectral Resolution Mass Spectrometry Imaging Reveals Reduced AMP and Elevated ATP Levels in Glomeruli of Diabetic Mice”
Annual Meeting: Abstract Sessions, Abstract TH-PO463
Time 10:00 AM ET - 12:00 PM
Friday November 14 - “Urine Metabolomic Profile Correlates with Renal Function and Changes During Atrasentan Therapy in Patients with Diabetes and Nephropathy”
Annual Meeting: Abstract Sessions, Abstract FR-PO773
Time 10:00 AM ET - 12:00 PM
Saturday November 15: “Diabetes Mellitus and Obesity: Basic Experimental - II”
Annual Meeting: Abstract Sessions, Abstract SA-PO308
Time: 10:00 AM ET - 12:00 PM
About ClinMet
ClinMet, founded in 2011, is a privately held company based in San Diego, CA that provides pharmaceutical companies with clinically relevant insights and actionable information about drug efficacy, safety and mechanism of action using its proprietary urine metabolomics biomarker platform for diabetes, kidney disease, obesity and cardiovascular disease. ClinMet applies its unique combination of in-depth clinical insights, proprietary metabolomics expertise, and computational know-how to improve the speed and success rate of drug development. The company helps drug developers to efficiently transform promising compounds into safe and effective medicines and to effectively develop and implement their companion diagnostics strategy. For more information, please visit the ClinMet website at http://www.clinmet.com.
###
Joan Kureczka, Kureczka/Martin Associates, +1 (415) 821-2413, [email protected]
Share this article